跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Irinotesin Concentrate for Solution for Infusion 20mg/ ml - HSA Drug Approval Details
Approvals
/
HSA
/
Irinotesin Concentrate for Solution for Infusion 20mg/ ml
Approved
THERAPEUTIC
Irinotesin Concentrate for Solution for Infusion 20mg/ ml
S.C. Sindan-Pharma S.R.LACTAVIS ITALY S.P.A.
🇸🇬 Health Sciences Authority
Approval Date
Aug 26, 2010
Approval ID
6a4493a80cf0661f
Company
S.C. Sindan-Pharma S.R.LACTAVIS ITALY S.P.A.
Type
Therapeutic
Approval Details
Approval Id
6a4493a80cf0661f
Drug Name
Irinotesin Concentrate for Solution for Infusion 20mg/ ml
Product Name
Irinotesin Concentrate for Solution for Infusion 20mg/ ml
Approval Number
SIN13857P
Approval Date
2010-08-26
Registrant
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence Holder
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Drug Type
Therapeutic
Forensic Classification
Prescription Only
Dosage Form
INFUSION, SOLUTION CONCENTRATE
Route Of Administration
INTRAVENOUS
Atc Code
L01XX19
Atc Item Name
xl 01 xx 19
Pharma Manufacturer Name
TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Company Detail Path
/organization/teva-pharmaceutical-investments-singapore-pte-ltd
Active Ingredients
Irinotecan Hydrochloride Trihydrate
20mg/ ml
IRINOTECAN HYDROCHLORIDE TRIHYDRATE
20 MG/ML
Approved
Quick Info
Agency
HSA
Country
🇸🇬
Approval Date
Aug 26, 2010
Approval ID
6a4493a80cf0661f
Type
Therapeutic
Back to HSA Approvals
